Reversal of hippocampal neuronal maturation by serotonergic antidepressants.
Serotonergic antidepressant drugs have been commonly used to treat mood and anxiety disorders, and increasing evidence suggests potential use of these drugs beyond current antidepressant therapeutics. Facilitation of adult neurogenesis in the hippocampal dentate gyrus has been suggested to be a candidate mechanism of action of antidepressant drugs, but this mechanism may be only one of the broad effects of antidepressants. Here we show a distinct unique action of the serotonergic antidepressant fluoxetine in transforming the phenotype of mature dentate granule cells. Chronic treatments of adult mice with fluoxetine strongly reduced expression of the mature granule cell marker calbindin. The fluoxetine treatment induced active somatic membrane properties resembling immature granule cells and markedly reduced synaptic facilitation that characterizes the mature dentate-to-CA3 signal transmission. These changes cannot be explained simply by an increase in newly generated immature neurons, but best characterized as "dematuration" of mature granule cells. This granule cell dematuration developed along with increases in the efficacy of serotonin in 5-HT(4) receptor-dependent neuromodulation and was attenuated in mice lacking the 5-HT(4) receptor. Our results suggest that serotonergic antidepressants can reverse the established state of neuronal maturation in the adult hippocampus, and up-regulation of 5-HT(4) receptor-mediated signaling may play a critical role in this distinct action of antidepressants. Such reversal of neuronal maturation could affect proper functioning of the mature hippocampal circuit, but may also cause some beneficial effects by reinstating neuronal functions that are lost during development.
Kobayashi
Katsunori
K
Department of Pharmacology, Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan. kkatsu-tky@umin.ac.jp
Ikeda
Yumiko
Y
Sakai
Atsushi
A
Yamasaki
Nobuyuki
N
Haneda
Eisuke
E
Miyakawa
Tsuyoshi
T
Suzuki
Hidenori
H
D000375:Aging; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D064026:Calbindins; D015536:Down-Regulation; D005473:Fluoxetine / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects* / Q000254:growth & development* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D044422:Receptors, Serotonin, 5-HT4 / Q000172:deficiency / Q000378:metabolism; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*
D018687:Antidepressive Agents, Second-Generation; D015415:Biomarkers; D064026:Calbindins; D064030:S100 Calcium Binding Protein G; D005473:Fluoxetine; D044422:Receptors, Serotonin, 5-HT4; D012701:Serotonin
Brain Res. 2004 Aug 13;1017(1-2):21-31
15261095
J Neurosci. 2009 Apr 15;29(15):5000-8
19369569
Science. 2008 Apr 18;320(5874):385-8
18420937
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102
12551730
Eur J Neurosci. 2002 Jan;15(2):329-44
11849299
Annu Rev Physiol. 2002;64:355-405
11826273
Neuron. 2001 Jan;29(1):209-16
11182092
Mol Neurobiol. 2009 Feb;39(1):24-36
19130314
J Comp Neurol. 1979 Jun 1;185(3):423-59
86549
Science. 2003 Aug 8;301(5634):805-9
12907793
J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):159-69
16553536
Mol Psychiatry. 2008 Feb;13(2):119-21
18202694
CNS Neurosci Ther. 2008 Summer;14(2):153-64
18482027
Nature. 2004 May 13;429(6988):184-7
15107864
Psychopharmacology (Berl). 2008 Nov;200(4):557-72
18629477
PLoS One. 2009;4(4):e5320
19399173
J Neurosci. 2000 Dec 15;20(24):9104-10
11124987
Eur J Neurosci. 2003 Nov;18(10):2707-12
14656319
J Neurosci. 2007 Oct 3;27(40):10906-11
17913924
Neuroscience. 2007 Jan 5;144(1):110-8
17055173
Brain Res Dev Brain Res. 1996 Oct 23;96(1-2):97-108
8922672
J Neurosci. 2008 Jun 11;28(24):6272-80
18550770
Science. 2007 Aug 10;317(5839):819-23
17615305
J Neurosci. 2008 Feb 6;28(6):1374-84
18256257
J Physiol. 2003 Nov 15;553(Pt 1):37-48
12963803
Mol Psychiatry. 2008 Sep;13(9):858-72
18332879
Mol Cell Neurosci. 2003 Nov;24(3):603-13
14664811
J Comp Neurol. 2008 Aug 1;509(4):372-81
18512685
J Comp Neurol. 2005 Apr 18;484(4):418-39
15770652
Prog Brain Res. 2007;163:601-13
17765740
Mol Cell Neurosci. 2008 Nov;39(3):372-83
18718867
Neurosci Lett. 2009 Feb 20;451(2):148-51
19135130
Neuron. 2007 May 24;54(4):559-66
17521569
J Neurobiol. 2000 Feb 5;42(2):248-57
10640331
Neuropharmacology. 2007 Feb;52(2):552-61
17049952
Life Sci. 2003 May 23;73(1):1-17
12726882
J Comp Neurol. 2001 Jul 9;435(4):406-17
11406822
Neuropsychopharmacology. 2008 Jan;33(2):406-17
17429410
Cell. 2008 Feb 22;132(4):645-60
18295581
Neuron. 2004 Feb 5;41(3):445-54
14766182
Mol Brain. 2008 Sep 10;1:6
18803808
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10409-14
9294224
J Physiol. 2004 Nov 15;561(Pt 1):27-37
15358807
Neuroscience. 2006 Sep 29;142(1):49-58
16844311
Int J Dev Neurosci. 2007 Aug;25(5):265-74
17616293
Eur J Neurosci. 2006 Aug;24(4):1053-62
16930432
Neuropsychopharmacology. 2008 May;33(6):1312-22
17609676